Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure
Atosiban, administered at embryo transfer, can improve the implantation rate and the clinical pregnancy rate in patients with repeated implantation failure undergoing IVF-ET (in-vitro fertilization and embryo transfer).
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure|
- Clinical pregnancy [ Time Frame: 5 weeks after intervention ] [ Designated as safety issue: No ]
|Study Start Date:||March 2011|
|Study Completion Date:||September 2011|
|Primary Completion Date:||August 2011 (Final data collection date for primary outcome measure)|
Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.
Other Name: Tractocile
Atosiban is a mixed oxytocin and vasopressin V1A receptor antagonist.Combined antagonism at oxytocin and vasopressin V1A receptors reduces uterine contractions with a corresponding decrease in intrauterine production of prostaglandin F2alpha and improved uterine blood supply. These effects are of potential benefit for implantation support during IVF-ET cycles.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01493440
|IVFAS, An Sinh Hospital|
|Ho Chi Minh City, Ho Chi Minh, Vietnam, 8|
|Principal Investigator:||Lan TN Vuong, MD||University of Medicine and Pharmacy of Ho Chi Minh City|